23 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Pharmaceuticals Our Pharmaceuticals business has a broad portfolio of innovative and established medicines.
We are focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas.
Pharmaceuticals sales were up 7% AER, In 2017 we had two significant 3% CER, reflecting the continued strong Pharmaceutical approvals: Trelegy Ellipta, growth of Nucala and our Ellipta portfolio which provides three medicines in a once in Respiratory, and Tivicay and Triumeq a day, single inhaler to treat COPD: and Dave, oncology scientist, UK in HIV.
Juluca, the first 2-drug regimen, once-daily, We have joined forces with our partners to rapidly single pill for HIV, which helps to reduce evolve the science of immuno-oncology, in one area we are working on increasing the ability of the amount of medicines patients need.
the bodys immune system to help detect and Pharmaceuticals turnover m attack cancer cells.
Respiratory 6,991 HIV 4,350 Immuno-inflammation 377 Established Pharmaceuticals 5,558 Total 17,276 Fran, cancer survivor and GSK employee Whats next Innovation in Pharmaceuticals See pages 2427 Performance in Pharmaceuticals See pages 2829 We report on our Trust priority Footnote across all three businesses We use a number of adjusted, non-IFRS, measures to report performance, as See pages 4251 described on page 58.
